Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen

Ayaka Washizaki; Asako Murayama; Megumi Murata; Tomoko Kiyohara; Keigo Yato; Norie Yamada; Hussein Hassan Aly; Tomohisa Tanaka; Kohji Moriishi; Hironori Nishitsuji; Kunitada Shimotohno; Yasumasa Goh; Ken J. Ishii; Hiroshi Yotsuyanagi; Masamichi Muramatsu; Koji Ishii; Yoshimasa Takahashi; Ryosuke Suzuki; Hirofumi Akari; Takanobu Kato

doi:10.1038/s41467-022-32910-z

Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen

Ayaka Washizaki, Asako Murayama, Megumi Murata, Tomoko Kiyohara, Keigo Yato, Norie Yamada, Hussein Hassan Aly, Tomohisa Tanaka, Kohji Moriishi, Hironori Nishitsuji, Kunitada Shimotohno, Yasumasa Goh, Ken J. Ishii, Hiroshi Yotsuyanagi, Masamichi Muramatsu, Koji Ishii, Yoshimasa Takahashi, Ryosuke Suzuki, Hirofumi Akari, Takanobu Kato

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We investigate an HB vaccine consisting of large-HBsAg that overcomes the shortcomings of the current HB vaccine. Yeast-derived large-HBsAg is immunized into rhesus macaques, and the neutralizing activities of the induced antibodies are compared with those of the current HB vaccine. Although the antibodies induced by the current HB vaccine cannot prevent HBV infection with VEMs, the large-HBsAg vaccine-induced antibodies neutralize those infections. The HBV genotypes that exhibited attenuated neutralization via these vaccines are different. Here, we show that the HB vaccine consisting of large-HBsAg is useful to compensate for the shortcomings of the current HB vaccine. The combined use of these HB vaccines may induce antibodies that can neutralize HBV strains with VEMs or multiple HBV genotypes.

Original language	English
Article number	5207
Journal	Nature communications
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41467-022-32910-z
Publication status	Published - 12-2022
Externally published	Yes

All Science Journal Classification (ASJC) codes

General Chemistry
General Biochemistry,Genetics and Molecular Biology
General Physics and Astronomy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41467-022-32910-z

Cite this

Washizaki, A., Murayama, A., Murata, M., Kiyohara, T., Yato, K., Yamada, N., Aly, H. H., Tanaka, T., Moriishi, K., Nishitsuji, H., Shimotohno, K., Goh, Y., Ishii, K. J., Yotsuyanagi, H., Muramatsu, M., Ishii, K., Takahashi, Y., Suzuki, R., Akari, H., & Kato, T. (2022). Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen. Nature communications, 13(1), Article 5207. https://doi.org/10.1038/s41467-022-32910-z

@article{6284f58a565e4fb2b8f31ae2c2846e4d,

title = "Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen",

abstract = "Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We investigate an HB vaccine consisting of large-HBsAg that overcomes the shortcomings of the current HB vaccine. Yeast-derived large-HBsAg is immunized into rhesus macaques, and the neutralizing activities of the induced antibodies are compared with those of the current HB vaccine. Although the antibodies induced by the current HB vaccine cannot prevent HBV infection with VEMs, the large-HBsAg vaccine-induced antibodies neutralize those infections. The HBV genotypes that exhibited attenuated neutralization via these vaccines are different. Here, we show that the HB vaccine consisting of large-HBsAg is useful to compensate for the shortcomings of the current HB vaccine. The combined use of these HB vaccines may induce antibodies that can neutralize HBV strains with VEMs or multiple HBV genotypes.",

author = "Ayaka Washizaki and Asako Murayama and Megumi Murata and Tomoko Kiyohara and Keigo Yato and Norie Yamada and Aly, {Hussein Hassan} and Tomohisa Tanaka and Kohji Moriishi and Hironori Nishitsuji and Kunitada Shimotohno and Yasumasa Goh and Ishii, {Ken J.} and Hiroshi Yotsuyanagi and Masamichi Muramatsu and Koji Ishii and Yoshimasa Takahashi and Ryosuke Suzuki and Hirofumi Akari and Takanobu Kato",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41467-022-32910-z",

language = "English",

volume = "13",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Washizaki, A, Murayama, A, Murata, M, Kiyohara, T, Yato, K, Yamada, N, Aly, HH, Tanaka, T, Moriishi, K, Nishitsuji, H, Shimotohno, K, Goh, Y, Ishii, KJ, Yotsuyanagi, H, Muramatsu, M, Ishii, K, Takahashi, Y, Suzuki, R, Akari, H & Kato, T 2022, 'Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen', Nature communications, vol. 13, no. 1, 5207. https://doi.org/10.1038/s41467-022-32910-z

TY - JOUR

T1 - Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen

AU - Washizaki, Ayaka

AU - Murayama, Asako

AU - Murata, Megumi

AU - Kiyohara, Tomoko

AU - Yato, Keigo

AU - Yamada, Norie

AU - Aly, Hussein Hassan

AU - Tanaka, Tomohisa

AU - Moriishi, Kohji

AU - Nishitsuji, Hironori

AU - Shimotohno, Kunitada

AU - Goh, Yasumasa

AU - Ishii, Ken J.

AU - Yotsuyanagi, Hiroshi

AU - Muramatsu, Masamichi

AU - Ishii, Koji

AU - Takahashi, Yoshimasa

AU - Suzuki, Ryosuke

AU - Akari, Hirofumi

AU - Kato, Takanobu

PY - 2022/12

Y1 - 2022/12

N2 - Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We investigate an HB vaccine consisting of large-HBsAg that overcomes the shortcomings of the current HB vaccine. Yeast-derived large-HBsAg is immunized into rhesus macaques, and the neutralizing activities of the induced antibodies are compared with those of the current HB vaccine. Although the antibodies induced by the current HB vaccine cannot prevent HBV infection with VEMs, the large-HBsAg vaccine-induced antibodies neutralize those infections. The HBV genotypes that exhibited attenuated neutralization via these vaccines are different. Here, we show that the HB vaccine consisting of large-HBsAg is useful to compensate for the shortcomings of the current HB vaccine. The combined use of these HB vaccines may induce antibodies that can neutralize HBV strains with VEMs or multiple HBV genotypes.

AB - Although the current hepatitis B (HB) vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations (VEMs) has been reported. We investigate an HB vaccine consisting of large-HBsAg that overcomes the shortcomings of the current HB vaccine. Yeast-derived large-HBsAg is immunized into rhesus macaques, and the neutralizing activities of the induced antibodies are compared with those of the current HB vaccine. Although the antibodies induced by the current HB vaccine cannot prevent HBV infection with VEMs, the large-HBsAg vaccine-induced antibodies neutralize those infections. The HBV genotypes that exhibited attenuated neutralization via these vaccines are different. Here, we show that the HB vaccine consisting of large-HBsAg is useful to compensate for the shortcomings of the current HB vaccine. The combined use of these HB vaccines may induce antibodies that can neutralize HBV strains with VEMs or multiple HBV genotypes.

UR - http://www.scopus.com/inward/record.url?scp=85137255091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137255091&partnerID=8YFLogxK

U2 - 10.1038/s41467-022-32910-z

DO - 10.1038/s41467-022-32910-z

M3 - Article

C2 - 36064848

AN - SCOPUS:85137255091

SN - 2041-1723

VL - 13

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 5207

ER -

Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this